ClinicalTrials.gg
TerminatedNCT05911243Updated Nov 3, 2026Results posted

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

An interventional study of Acupressure Therapy and Best Practice in Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 and Clinical Stage II Gastric Cancer AJCC v8, sponsored by University of Washington. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Washington · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Study closed per SRC Low Accrual Policy.
Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
1,441st of 1,573
3 · median 37
Started
2024
with 67 others
No phase
246 of 1,850
49 open now
Registered
1,597th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 1,441st largest by enrollment of the 1,573 interventional ones that give a count, is one of 68 that started in 2024, is one of 246 with no phase, and was the 1,597th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatment tolerance and adherence, and reduces overall patient quality of life. Auricular acupressure is a form of micro-acupuncture that exerts its effect by stimulating the central nervous system using adhesive taped pellets applied to specific locations on the external ear. The use of these pellets to deliver auricular acupressure has been shown to improve pain, fatigue, insomnia, nausea and vomiting, depression, and quality of life in both cancer and non-cancer settings. Auricular acupressure is a safe, inexpensive, and non-invasive approach to addressing cancer-related symptoms and treatment side-effects and may be effective at improving appetite and weight loss in stage II-IV gastric, esophageal, and pancreatic cancer patients.

Read the detailed description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.

ARM II: Patients receive usual care on study. Patients also undergo collection of blood samples on study.

After completion of study treatment, patients in Arm II are followed up at 8 weeks after active treatment ends.

03

Conditions studied

  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage II Gastric Cancer AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Stage II Pancreatic Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 18-65 years of age
  • Stage II-IV gastric, esophageal, or pancreatic cancer
  • Appetite score on visual analog scale ≤ 70/100
  • At least 60 days of planned systemic treatment, whether already initiated or scheduled to be initiated
  • Access to phone and electronic device for study contacts and questionnaires
  • Willing and able to attend 4 in-person auricular acupressure treatments at the Fred Hutch South Lake Union Clinic
  • Willing and able to perform 4 at-home self-applied treatments of auricular acupressure
  • Participants must not have received acupressure or acupuncture for low appetite within last 30 days
  • Participants must not be actively using , mirtazapine (Remeron), olanzapine (Zyprexa), or Marinol for appetite stimulation at baseline
  • Participants must be able to intake food orally and not require sole or supplemental intravenous nutrition at baseline
  • Participants must not have a history of physiological eating disorders (e.g., anorexia nervosa) in the last 3 years
  • Participants must not have a current known or diagnosed immunodeficiency
  • Participants must have an intact auricular pinna
  • Able to understand and willing to sign written in English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Arm I (acupressure therapy)

    Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.

    Procedure: Acupressure Therapy · Other: Best Practice · Procedure: Biospecimen Collection · Other: Questionnaire Administration

  • Active comparator
    Arm II (usual care)

    Patients receive usual care on study. Patients also undergo collection of blood samples on study.

    Other: Best Practice · Procedure: Biospecimen Collection · Other: Questionnaire Administration

Interventions

  • ProcedureAcupressure Therapy

    Undergo auricular acupressure

    Also known as: Acupressure, Ischemic Compression

  • OtherBest Practice

    Receive usual care

    Also known as: standard of care, standard therapy

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • OtherQuestionnaire Administration

    Ancillary studies

    Also known as: Quality of Life Assessment

06

What researchers measure

Primary outcomes

  1. Accrual (Feasibility)

    Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period.

    Time frame: Up to 2 years, during study accrual

  2. Retention (Feasibility)

    Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit.

    Time frame: Up to 8 weeks

  3. Intervention Adherence (Feasibility)

    Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8.

    Time frame: Up to 8 weeks

  4. Intervention Fidelity (Feasibility)

    Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis.

    Time frame: Up to 8 weeks

  5. Acceptability (Feasibility)

    Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews.

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Change in Appetite

    As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.

    Time frame: Baseline to week 4

  2. Change in Appetite

    As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.

    Time frame: Baseline to week 8

  3. Change in Body Weight (kg)

    Analyses will assess change in each outcome as a change from baseline to week 4.

    Time frame: Baseline to week 4

  4. Change in Body Weight (kg)

    Analyses will assess change in each outcome as a change from baseline to week 8.

    Time frame: Baseline to week 8

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm I (Acupressure Therapy)Arm II (Usual Care)
Started03
Completed01
Not completed02
Withdrew: Lost to follow-up01
Withdrew: Death01

Outcome measures

PrimaryAccrual (Feasibility)

Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period.

Time frame:
Up to 2 years, during study accrual
Reported as:
Count of participants · Participants
Accrual (Feasibility)
ParticipantsArm I (Acupressure Therapy)Arm II (Usual Care)
Accrual (Feasibility)—3
PrimaryRetention (Feasibility)

Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Retention (Feasibility)
ParticipantsArm I (Acupressure Therapy)Arm II (Usual Care)
Retention (Feasibility)—1
PrimaryIntervention Adherence (Feasibility)

Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8.

Time frame:
Up to 8 weeks

No measurements were reported for this outcome.

PrimaryIntervention Fidelity (Feasibility)

Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis.

Time frame:
Up to 8 weeks

No measurements were reported for this outcome.

PrimaryAcceptability (Feasibility)

Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews.

Time frame:
Up to 16 weeks

No measurements were reported for this outcome.

SecondaryChange in Appetite

As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.

Time frame:
Baseline to week 4
Reported as:
Median · score on a scale
Change in Appetite
score on a scaleArm I (Acupressure Therapy)Arm II (Usual Care)
Change in Appetite—1.5 (-1 to 2)
SecondaryChange in Appetite

As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.

Time frame:
Baseline to week 8
Reported as:
Number · score on a scale
Change in Appetite
score on a scaleArm I (Acupressure Therapy)Arm II (Usual Care)
Change in Appetite—-3
SecondaryChange in Body Weight (kg)

Analyses will assess change in each outcome as a change from baseline to week 4.

Time frame:
Baseline to week 4
Reported as:
Number · kg
Change in Body Weight (kg)
kgArm I (Acupressure Therapy)Arm II (Usual Care)
Change in Body Weight (kg)—-0.27
SecondaryChange in Body Weight (kg)

Analyses will assess change in each outcome as a change from baseline to week 8.

Time frame:
Baseline to week 8
Reported as:
Number · kg
Change in Body Weight (kg)
kgArm I (Acupressure Therapy)Arm II (Usual Care)
Change in Body Weight (kg)—-1.72

Adverse events

Collected over Adverse events were collected throughout the intervention period (8 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (Acupressure Therapy)———
Arm II (Usual Care)1/3 (33.3%)0/3 (0%)0/3 (0%)

Baseline characteristics

Three participants were randomized into Arm II (usual care). No participants were randomized into Arm I (acupressure therapy).

Age, Categorical
Age, Categorical(Participants)Arm I (Acupressure Therapy)Arm II (Usual Care)Total
<=18 years—00
Between 18 and 65 years—33
>=65 years—00
Age, Continuous
Age, Continuous(years)Arm I (Acupressure Therapy)Arm II (Usual Care)Total
Mean—54 (45 to 62)54 (45 to 62)
Sex: Female, Male
Sex: Female, Male(Participants)Arm I (Acupressure Therapy)Arm II (Usual Care)Total
Female—11
Male—22
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (Acupressure Therapy)Arm II (Usual Care)Total
American Indian or Alaska Native—00
Asian—00
Native Hawaiian or Other Pacific Islander—00
Black or African American—00
White—33
More than one race—00
Unknown or Not Reported—00
Region of Enrollment
Region of Enrollment(participants)Arm I (Acupressure Therapy)Arm II (Usual Care)Total
United States—33
08

Study locations

1 site
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in published articles after de-identification may be made available upon request (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 6 months and ending 36 months after publication of results or study protocol, as requested.

Access criteria: Researchers and investigators who: 1) provide a methodologically sound proposal to expand on aims in the original, approved proposal; and/or 2) aim to conduct individual, participant-level meta-analyses. Proposals should be directed to blangley@fredhutch.org. To gain access, data requestors will need to sign a data access agreement.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jul 2025, 11 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2023
First posted
Jun 20, 2023
StartActual
Jul 22, 2024
Primary completionActual
Jul 9, 2025
CompletionActual
Jul 9, 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedAccrual (feasibilityFeasibility)Time frame: Up to 15 months → Up to 2 years, during study accrual
  • EditedRetention (feasibilityFeasibility)Time frame: Up to 8 weeks
  • EditedIntervention adherenceAdherence (feasibilityFeasibility)Time frame: Up to 8 weeks
  • EditedIntervention fidelityFidelity (feasibilityFeasibility)Time frame: Up to 8 weeks
  • EditedAcceptability (feasibilityFeasibility)Time frame: Up to 16 weeks
Nov 3, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedChange in appetiteAppetiteTime frame: Baseline to week 4
  • EditedChange in appetiteAppetiteTime frame: Baseline to week 8
  • EditedChange in body weightBody Weight (kg)Time frame: Baseline to week 4
  • EditedChange in body weightBody Weight (kg)Time frame: Baseline to week 8
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedAccrual (feasibilityFeasibility)Time frame: Up to 15 months → Up to 2 years, during study accrual
    • EditedRetention (feasibilityFeasibility)Time frame: Up to 8 weeks
    • EditedIntervention adherenceAdherence (feasibilityFeasibility)Time frame: Up to 8 weeks
    • EditedIntervention fidelityFidelity (feasibilityFeasibility)Time frame: Up to 8 weeks
    • EditedAcceptability (feasibilityFeasibility)Time frame: Up to 16 weeks
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedChange in appetiteAppetiteTime frame: Baseline to week 4
    • EditedChange in appetiteAppetiteTime frame: Baseline to week 8
    • EditedChange in body weightBody Weight (kg)Time frame: Baseline to week 4
    • EditedChange in body weightBody Weight (kg)Time frame: Baseline to week 8
    + 4 other changes: verification date, responsible party, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05911243
Responsible party
Blake Langley (Staff Scientist, University of Washington) — Principal investigator
First posted
Jun 20, 2023
Start date
Jul 22, 2024
Primary completion
Jul 9, 2025
Completion
Jul 9, 2025
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Blake Langley
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion